Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature
View / Open Files
Publication Date
2017-03Journal Title
Rheumatology
ISSN
1462-0324
Publisher
British Society for Rheumatology
Volume
57
Issue
7
Pages
1309-1310
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Nakagomi, D., Kronbichler, A., Witte, T., Mohammad, A. J., & Jayne, D. (2017). Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology, 57 (7), 1309-1310. https://doi.org/10.1093/rheumatology/kex493
Abstract
Sir, Takayasu arteritis (TAK) is a granulomatous vasculitis affecting large vessels, including the aorta and its main branches. It has a female preponderance and the diagnosis is usually made in the second or third decade of life. Imperfect activity scores mainly relying on a modified Birmingham Vasculitis Activity Score and scores including imaging have been proposed [1]. Treatment strategies used in the management of TAK are not evidence-based due to a paucity of randomised controlled trials. In general, disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX), azathioprine (AZA), mycophenolate mofetil (MMF), leflunomide (LEF) and cyclophosphamide (CYC) in selected cases, alongside steroids are considered as mainstay of treatment. Furthermore, biologic agents such as TNF-α inhibitors, especially infliximab (IFX), interleukin-6 blockade with tocilizumab (TCZ) and B-cell depletion with rituximab (RTX) attracted attention due to efficacy in mainly refractory TAK cases [2].
Identifiers
External DOI: https://doi.org/10.1093/rheumatology/kex493
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330619
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.